GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Capex-to-Operating-Cash-Flow

WXIBF (WuXi Biologics (Cayman)) Capex-to-Operating-Cash-Flow : 1.43 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

WuXi Biologics (Cayman)'s Capital Expenditure for the six months ended in Jun. 2024 was $-257.40 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2024 was $179.49 Mil.

Hence, WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow for the six months ended in Jun. 2024 was 1.43.


WuXi Biologics (Cayman) Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Capex-to-Operating-Cash-Flow Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.68 3.20 1.90 1.06 0.91

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 0.78 0.93 0.87 1.43

Competitive Comparison of WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow falls into.



WuXi Biologics (Cayman) Capex-to-Operating-Cash-Flow Calculation

WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-592.492) / 653.723
=0.91

WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-257.403) / 179.486
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (OTCPK:WXIBF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


WuXi Biologics (Cayman) Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.